The initially reported PFS and OS (median 7.6 months and 12.8 months respectively) were considerably higher than historical results in chemotherapy refractory CRC patients with KRAS mutated tumours [28] and chemotherapy refractory CRC patients in general [29–31]. This evidence concerns the gene KRAS and neoplasm.